Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 63629-9634

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 63629-9634). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Carvedilol 1)

Structure (Carvedilol 1)
Chemical structure of carvedilol phosphate showing its molecular arrangement including aromatic rings and functional groups, with annotations for phosphate and water molecules.*
FDA Label Image

Figure-1 (Carvedilol Figure1)

Figure-1 (Carvedilol Figure1)
A Kaplan-Meier curve chart showing percent mortality over time in months, comparing two groups labeled as Placebo and Carvedilol. The vertical axis represents percent mortality up to 30%, and the horizontal axis shows time from 0 to 21 months. The Carvedilol group shows consistently lower mortality than the Placebo group, with a p-value of 0.0014 indicated on the graph.*
FDA Label Image

Figure-2 (Carvedilol Spl Figure 2)

Figure-2 (Carvedilol Spl Figure 2)
A forest plot showing hazard ratios for various patient subgroups including sex, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use, with confidence intervals depicted by horizontal lines and a vertical dashed line at a hazard ratio of 1.0 as reference.*
FDA Label Image

Figure-3 (Carvedilol Figure3)

Figure-3 (Carvedilol Figure3)
A line graph comparing percent mortality over time (in months) between two groups labeled Placebo and Carvedilol. The graph shows a mortality trend increasing over 24 months, with the Carvedilol group having a lower mortality percentage than the Placebo group, and includes a statistical significance marker (P = 0.03).*
FDA Label Image

Figure-4 (Carvedilol Spl Figure 4)

Figure-4 (Carvedilol Spl Figure 4)
A forest plot displaying hazard ratios for various patient subgroups related to cardiovascular conditions and treatments. The plot includes subgroups such as age, sex, timing of randomization post-myocardial infarction (MI), prior use of beta-blockers, Killip class, presence of diabetes, hypertension, heart rate levels, and other clinical factors. Hazard ratios with confidence intervals are plotted on a horizontal axis ranging from 0.4 to 1.3. The chart visually compares risk across patient groups for a clinical study context.*
FDA Label Image

Figure (Carvedilol 2)

Figure (Carvedilol 2)
Two line graphs illustrate changes in systolic and diastolic blood pressure (SBP and DBP) over 24 hours after a morning dose of Carvedilol Phosphate extended-release capsules at 20 mg, 40 mg, and 80 mg strengths. The graphs plot time on the x-axis and blood pressure change on the y-axis, with smoothed trend lines for each dosage.*
FDA Label Image

Label (Lbl636299634)

Label (Lbl636299634)
Label for Carvedilol Phosphate extended-release capsules, 40 mg, oral dosage form. The label displays the NDC 63629-9634-1, quantity of 30 capsules, and includes storage instructions to keep between 20° to 25°C with temporary excursions allowed from 15° to 30°C. It also advises dispensing in a tight, light-resistant container. The label shows the product is repackaged by Bryant Ranch Prepack in Burbank, CA, and manufactured by Frontida BioPharm Inc. Barcodes and the BRP Pharmaceuticals logo are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.